ResMed Inc. Releases Transcript of FY 2025 Earnings Webcast

Reuters
02 Aug
ResMed Inc. Releases Transcript of FY 2025 Earnings Webcast

ResMed Inc. recently released the transcript of its Q4 fiscal year 2025 earnings call, held on July 31, 2025. The event, webcast live from Sydney, was hosted by Salli Schwartz, ResMed's Chief Investor Relations Officer, and featured key executives, including CEO Michael Farrell and CFO Brett Sandercock. Analysts from various financial institutions, such as RBC Capital Markets, Goldman Sachs, and Morgan Stanley, participated in the conference call. During the call, ResMed's management discussed the company's ongoing focus on its core business of helping over 2.3 billion people worldwide with sleep apnea, insomnia, and respiratory insufficiency. The executives emphasized the company's commitment to healthcare delivery through its market-leading software. They also touched upon the potential resumption of the competitive bidding program by CMS, with the CEO stating, "Resmed has a long-standing track record of engaging constructively with the US government." The full transcript can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ResMed Inc. published the original content used to generate this news brief on August 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10